BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.510
-0.090 (-5.63%)
At close: Mar 20, 2026, 4:00 PM EDT
1.539
+0.029 (1.95%)
After-hours: Mar 20, 2026, 7:49 PM EDT

BioXcel Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
0.752.271.380.38--
Revenue Growth (YoY)
-66.96%64.20%268.00%---
Cost of Revenue
0.962.141.260.02--
Gross Profit
-0.210.120.120.36--
Selling, General & Admin
20.7834.4983.4168.7654.2324.3
Research & Development
29.4530.4484.3391.2452.7158
Other Operating Expenses
0.232.444.16---
Total Operating Expenses
50.4667.37171.9160106.9482.3
Operating Income
-50.67-67.25-171.78-159.65-106.94-82.3
Interest Income
1.112.65.652.530.04-0.16
Interest Expense
-16.62-15.13-13.31-8.21-0.040.03
Other Non-Operating Income (Expense)
-2.0320.170.39-0.43--
Total Non-Operating Income (Expense)
-17.547.65-7.27-6.110-0.13
Pretax Income
-68.21-59.6-179.05-165.76-106.93-82.43
Net Income
-68.21-59.6-179.05-165.76-106.93-82.17
Net Income to Common
-68.21-59.6-179.05-165.76-106.93-82.17
Shares Outstanding (Basic)
732221
Shares Outstanding (Diluted)
732221
Shares Change (YoY)
234.77%39.21%4.00%6.23%21.63%33.11%
EPS (Basic)
-9.70-23.51-98.33-94.72-64.80-60.64
EPS (Diluted)
-9.70-23.51-98.33-94.72-64.80-60.64
Free Cash Flow
-58.21-72.03-155.03-135.48-82.6-66.67
Free Cash Flow Per Share
-7.78-28.41-85.13-77.38-50.11-49.19
Gross Margin
-28.19%5.43%8.70%94.67%--
Operating Margin
-6738.30%-2967.56%-12447.97%-42572.00%--
Profit Margin
-9070.61%-2630.14%-12974.86%-44201.87%--
FCF Margin
-7741.22%-3178.60%-11233.77%-36128.00%--
EBITDA
-50.37-66.94-171.46-159.32-106.64-82.11
EBITDA Margin
-6698.01%-2953.93%-12424.93%-42484.80%--
EBIT
-50.67-67.25-171.78-159.65-106.94-82.3
EBIT Margin
-6738.30%-2967.56%-12447.97%-42572.00%--
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q